FindTrial
Sign In

GSK-3ß/ß-catenin signaling pathway in the regulation of pancreatic damage induced by clozapine

Study on the role and mechanism of GSK-3ß/ß-catenin Signaling pathway in the pancreatic damage induced by clozapine

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015856
Enrollment
Unknown
Registered
2018-04-24
Start date
2018-05-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

clozapine group:clozapine
other AP group:other antipsychotic
drug-naive group:drug-naive
control group:control

Sponsors

Chaohu Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with a diagnosis of schizophrenia aged 18-50 years old, treated with clozapine or other antipsychotics alone for more than 8 weeks.

Exclusion criteria

Exclusion criteria: patients with pancreatic injury factors or severe somatic disease, and pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
GSK-3ß/ß-catenin;Inflammatory cytokines;—

Countries

China

Contacts

Public ContactHuanzhong Liu

Chaohu Hospital of Anhui Medical University

huanzhongliu@126.com+86 13855152219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026